Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Almirall S.A.
LBTSFAlmirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain. Address: Ronda General Mitre, 151, Barcelona, Spain, 08022
Analytics
Zielpreis von Wall Street
12.49 EURKGV
–Dividendenrendite
1.72 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen LBTSF
Dividenden-Analyse LBTSF
Dividendenwachstum über 5 Jahre
–Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
112 %Verlauf der Dividende LBTSF
Bewertung der Aktie LBTSF
Finanzen LBTSF
Ergebnisse | 2019 | Dynamik |